Avanços promissores na tecnologia de punção transeptal: Ensaio clínico no Paraguai mostra resultados positivos
Protaryx Medical has completed a first-in-human study showing the significant potential of its advanced transseptal puncture technology.
January 30, 2025: PROTARYX Medical, an innovative company in the medical device field, has announced encouraging results from its ongoing clinical study conducted in Paraguay. The trial focuses on their novel transseptal puncture technology, designed to improve minimally invasive cardiac procedures.
Study Highlights
Trial Location: The study is being carried out in Paraguay, underscoring Latin America's growing importance as a destination for clinical research in the medical device sector.
Innovative Technology: PROTARYX's device is designed to facilitate precise access to the left side of the heart during complex cardiac procedures.
Promising Results: Preliminary data suggests a significant improvement in the accuracy and efficiency of transseptal puncture procedures.
Implications for the Industry
This advancement could represent an essential step in treating various cardiac conditions, offering physicians a more precise tool and potentially reducing the risks associated with minimally invasive cardiac procedures. The choice of Paraguay as the location for this clinical trial highlights the growing role of Latin America in medical device innovation and global clinical research. This development benefits the international medical community and positions the region as a crucial center for advancing medical technology.
